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CD47 is a “self marker” that is usually overexpressed 
on the surface of cancer cells to enable them to escape 
immunosurveillance. Recognition of CD47 by its 
receptor, signal regulatory protein α (SIRPα), which 
is expressed in the macrophages, inhibits phagocytic 
destruction of cancer cells by the macrophages. In 
this study, we have first shown that clinical isolates of 
human melanoma significantly upregulate CD47, pos-
sibly as a mechanism to defend themselves against 
the macrophages. We then exploited RNA interference 
(RNAi) technology to test the hypothesis that knock-
ing down CD47 in the tumor cells will render them 
targets for macrophage destruction; hence, creating a 
novel anti-cancer therapy. Anti-CD47 siRNA was encap-
sulated in a liposome-protamine-hyaluronic acid (LPH) 
nanoparticle (NP) formulation to address the challenge 
of targeted delivery of siRNA-based therapeutics in vivo. 
Efficient silencing of CD47 in tumor tissues with systemic 
administration of LPH(CD47) also significantly inhibited 
the growth of melanoma tumors. In a lung metastasis 
model, LPH(CD47) efficiently inhibited lung metastasis 
to about 27% of the untreated control. Moreover, no 
hematopoietic toxicity was observed in the animals that 
received multiple doses of LPH(CD47). Our findings indi-
cate CD47 as a potential prognostic marker for mela-
noma development as well as a target for therapeutic 
intervention with RNAi-based nanomedicines.
Received 3 December 2012; accepted 21 May 2013; advance online  
publication 18 June 2013. doi:10.1038/mt.2013.135
INTRODUCTION
Malignant melanoma is notorious for its aggressive invasive-
ness and metastasis, which always results in a poor prognosis for 
patients.1 Although melanoma cells exhibit a well-defined immu-
nogenicity,2,3 the overall results of the clinical immunotherapies 
are not satisfactory.4 The paradoxical observations suggest an 
immunosuppressive microenvironment in the tumor that is medi-
ated by different mechanisms, stemming from the secretion of 
immunosuppressive factors5,6 by stromal cells or lymphocytes. The 
microenvironment may also be created by the acquired immune 
tolerance of the melanoma cells.5,7
CD47 is a ubiquitous membrane receptor that belongs to the 
immunoglobulin (Ig) superfamily.8 The ligation between CD47 
and signal regulatory protein α (SIRPα), which is expressed on 
the macrophages, transduces an inhibitory signal that suppresses 
the phagocytic activity of macrophages.9 The ubiquitous expres-
sion of CD47 on the cell surface labels the cells with “the marker 
of self,” a mechanism through which macrophage discriminates 
between “self ” and “foreign” cells for contractile engulfment. 
CD47 expression levels are reported to be elevated in the cancer-
ous cells of several leukemic cell lines,10,11 bladder-tumor initiating 
cells,12 and lymphomas,13 which correlates with an adverse clinical 
prognosis. It is well acknowledged that inflammation and escape 
from immunosurveillance plays a critical role in promoting tumor 
progression. Over time, cancer cells can develop to express phe-
notypes that are less immunogenic.14 In this context, the over-
expression of CD47 is probably an outcome of immunoediting, 
which ensures that cancer cells escape elimination by the innate 
immune response of the macrophages.
A number of recent studies have demonstrated the therapeu-
tic efficacy of a function-blocking, anti-CD47, monoclonal anti-
body (mAbs) in the treatment of myeloma,15 leiomyosarcoma,16 
lymphoma,13,17 leukemia,18 and breast cancers.19 The administra-
tion of anti-CD47 mAbs inhibited tumor growth and prevented 
the metastasis by blocking the CD47/SIRPα interaction that pro-
tected the cancer cells from phagocytosis. Although antibody-
based therapy seemed to be efficacious, safety concerns arose due 
to the ubiquitous expression of CD47, particularly on hemato-
poietic cells. For example, mice that received an acute infusion 
of antibodies exhibited temporary anemia19 or neutropenia.11 To 
avoid these undesired side effects, we exploited RNA interference 
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(RNAi) therapy to target CD47 by systemically delivering siRNA 
formulated in the liposome-protamine-hyaluronic acid (LPH) 
nanoparticles (NPs). The LPH-NP is a well-established in vivo 
siRNA delivery system that is optimized for systemic delivery of 
siRNA to the tumor site with high specificity and efficiency.20,21
In the present study, we first examined the CD47 expression 
level in clinical human melanoma samples. With the confirmation 
of overexpression of CD47 in the melanoma, we hypothesized 
that the anti-phagocytic signal could be blocked by knockdown of 
CD47 with siRNA targeting CD47, which was systemically deliv-
ered using LPH-NPs. The hypothesis was tested in immune-toler-
ant murine melanoma cell line B16F10. The physiological effects 
on the melanoma cell after CD47 knockdown and its interaction 
with primary macrophages were studied in vitro. The pharmaco-
dynamics of CD47 targeting RNAi therapy was evaluated in syn-
geneic solid tumor and lung metastatic models. Last but not least, 
the systemic toxicities of the mice that received multiple doses of 
LPH-NP were examined.
RESULTS
CD47 expression is elevated in human melanoma 
tumors
The expression level of CD47 was evaluated within a panel of 16 
clinical samples from patients with malignant or metastatic mela-
nomas. The expression level of CD47 on normal, human epider-
mal melanocytes was used as a reference control. Results from 
western-blot analyses (Figure 1a) indicated that the expression 
level of CD47 was statistically higher (P = 0.0005) in all of the 
clinical melanoma samples than in the melanocytes (two-sided 
Wilcoxon signed-rank test) (Figure 1b). The overexpression of 
CD47 is not only observed in leukemia,18 but also in some solid 
tumors.19 In these tumors, the CD47 expression level could be 
considered an adverse prognostic factor.19
In vitro delivery of siRNA targeting CD47 in LPH-NPs 
silences the target gene in B16F10 cells
siRNA against CD47 was encapsulated into LPH-NPs through a 
stepwise, self-assembly process based on a well-established pro-
tocol.20 Briefly, the core of the NP was formed by mixing nega-
tively charged siRNA/hyaluronic acid and positively charged 
protamine at certain ratio so that the complex was slightly neg-
atively charged. The core was then coated with preformed cat-
ionic liposome prepared with DOTAP and Cholesterol (1/1 mol/
mol), resulting in high surface charge. After post-insertional 
pegylation, the final NPs were ~70 nm in diameter, with a sur-
face charge of 20 mV, as measured by a Zetasizer (Figure 2a). 
The decreased surface charge of the LPH-NP compared with that 
of a cationic liposome (~45 mV), indicates extensive PEGylation 
(Supplementary Figure S1). Such PEGylation reduces protein 
absorption and consequently decreases uptake by the reticulo-
endothelial system,22 extending the circulation time in the blood. 
A TEM analysis of the LPH-NP after negative staining with ura-
nyl acetate confirmed the particle size (Figure 2b). The efficiency 
for decreasing the expression of CD47 mediated by the LPH-NP 
(CD47) was evaluated in vitro in the murine melanoma cell line, 
B16F10. Twenty-four hours after transfection, CD47 protein 
levels were examined by western-blot analysis (Figure 2c). The 
delivery of anti-CD47 siRNA by commercial transfection agent 
TRANSIT, resulted in significant target gene knockdown, which 
showed sequence specificity of siRNA for this study. Moreover, 
the LPH-NPs loaded with anti-CD47 siRNA, rather than control 
siRNA, decreased CD47 protein levels, indicating the LPH for-
mulation did not cause any non-specific downregulation of the 
target gene.
The silencing effect was semiquantitatively confirmed using 
flow cytometric analysis (Figure 2d). Cells were stained with 
FITC-conjugated, anti-CD47 antibodies before analysis. The 
number of CD47 receptors on the cell-surface was then measured 
by the intensity of FITC fluorescence. The flowcytometry data 
showed that with 100% transfection efficiency, anti-CD47 siRNA 
delivered by LPH (CD47) significantly reduced the CD47 level to 
~3.6% compared with untreated cells. Minimal expression levels 
of CD47 on the red blood cells or platelets are sufficient for pro-
tecting cells from being engulfed by the macrophages.9 Therefore, 
complete removal of CD47 from mRNA is desired to create an 
opportunity for the macrophage to recognize the abnormal cancer 
cells and eradicate them.
Silencing of CD47 triggered the phagocytosis by 
macrophages
As an emerging therapeutic target, the physiological functions of 
CD47 have not been well elucidated. To evaluate the impact of 
CD47 silencing in vitro, a series of viability and invasion stud-
ies were performed on B16F10 cells after being transfected with 
LPH(CD47). First, loss of CD47 did not directly impair the short-
term proliferative capacity of cells based on the results of an MTS 
assay that was performed 2 days after transfection (Figure 3a). 
Figure 1 CD47 is elevated in clinical melanoma samples. (a) Western-
blot analysis of representative melanocyte and melanoma patients 
samples (1, Melanocyte; 2–6, clinical samples). GAPDH was used as a 
loading control. (b) Quantification of relative CD47 levels of clinical mel-
anoma samples compared with the melanocyte, based on densitometry 
analysis. The expression levels of CD47 on clinical melanoma samples 
are statistically higher than that of the melanocyte according to the two-
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By comparison, in untreated cells, the NP formulation with 
control siRNA did not cause any cytotoxicity. A matrigel inva-
sion assay was performed to examine if the knockdown of CD47 
would affect the migration and invasion abilities of the B16F10 
cells. The results showed no significant difference between the 
untreated cells and cells treated with anti-CD47 siRNA, indicat-
ing no direct enhancing or inhibition of invasiveness occurred 
(Figure 3b). A soft agar colony formation assay was conducted 
to evaluate the anchorage-independent growth. The number of 
colonies counted in the assay demonstrated that the silencing of 
CD47 enhanced neoplasticity of the B16F10 cells. Furthermore, 
the colonies formed by cells with CD47 knockdown were larger 
in size (Figure 3c). In addition, a dose-response cell prolifera-
tion assay was performed on the cells treated with various con-
centrations of anti-CD47 siRNA delivered by LPH-NPs. The data 
showed an enhanced proliferation in a dose-response manner. 
Higher anti-CD47 siRNA concentration led to higher prolif-
eration capacity, which showed the proliferative capacity of the 
tumor cells are reversely correlated to the CD47 expression level 
(Supplementary Figure S2).
To illustrate that silencing of CD47 enabled the phagocytosis of 
immune-system tolerant B16F10 cells in vitro, cells labeled with red 
fluorescent protein (RFP) were transfected with LPH(CD47) and 
incubated with primary murine macrophages that had been har-
vested from green fluorescent protein (GFP)-expressing, transgenic 
C57 mice. The interaction between the RFP-expressing B16F10 cells 
and the GFP-expressing macrophages was visualized using confocal 
microscopy (Figure 3d). The results indicated a phagocytic index of 
14% was induced by CD47 siRNA treatment versus 2% in control 
siRNA treated groups. These results were consistent with previous 
reports that blockade the interaction between the SIRPα and CD47 
compromises the immune tolerance of the B16F10 cells,19 making 
them vulnerable to murine macrophage recognition and engulf-
ment (Figure 3d).
Systemic delivery of anti-CD47 siRNA in LPH inhibited 
melanoma solid tumor development
Having demonstrated that the silencing of CD47 could induce 
phagocytosis in vitro, the efficacy of systemically delivering anti-
CD47 siRNA was evaluated in immune-competent syngeneic mice. 
Figure 2 In vitro transfection of LPH-NP knockdown CD47 expression in B16F10 cells. (a) Representative of size and zeta potential of LPH-NP 
determined by dynamic light scattering and coupled Doppler Laser Densitometry. The NPs were determined to be ~70 nm in diameter with a surface 
charge of 20 mV. (b) Representative of TEM image of LPH-NP after uranyl acetate negative staining. Scale bar: 100 nm. (c) Western-blot analysis of 
CD47 protein level (top) in the B16F10 melanoma cells 24 hours after transfection after treatment. GAPDH was used as a loading control (bottom). 
Lane 1: untreated; Lane 2: cells transfected with LPH(con siRNA); Lane 3: cells transfected with positive control TransIT (CD47 siRNA); Lane 4: cells 
transfected with LPH(CD47 siRNA). (d) Flowcytometry analysis of B16F10 cells treated with the LPH-NPs. Cells were stained with FITC-conjugated, 
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The flanks of C57 mice were inoculated with 2 × 105 murine mela-
noma B16F10 cells. The mice received intravenous (IV) injections 
of LPH(CD47) NPs every other day for a total of six injections. The 
delivery of CD47 siRNA in an LPH-NP formulation effectively 
inhibited solid tumor growth (Figure 4a,b). The tumor volume was 
reduced by ~93% at the endpoint compared to the untreated controls 
(P < 0.0001). As was reported by Chono et al.,20 the control siRNA 
loaded LPH-NP was minimally immunostimulatory over a broad 
range of dose (0.15–1.2 mg/kg), which was also tested in C57BL/6 
mice. Therefore, the low dose we used in animal studies should not 
induce significant levels of inflammatory cytokines, which could 
possibly enhance anti-tumor effect of the NPs. To demonstrate that 
the tumor growth inhibition was mediated by the macrophages, 
clodronate encapsulated in the liposomes was intraperitoneally 
injected into the mice to deplete the macrophages before treatment 
with LPH(CD47). Liposomal clodronate has been developed and 
successfully applied in the selective depletion of macrophages in 
some immune23,24 or cancer therapies.25 We observed that the deple-
tion of the macrophages completely abolished the inhibition effect 
mediated by LPH(CD47) (P < 0.0001). The combinatorial treat-
ment of liposomal clodronate and LPH(CD47) resulted in larger 
tumor volumes compared to the untreated tumors (P < 0.001). 
Levels of CD47 protein knockdown were measured using immu-
nofluorescence staining with FITC-conjugated, anti-CD47 anti-
body. The epifluorescent image demonstrated an effective silencing 
of the “self-marker” after treatment with LPH(CD47) (Figure 4c). 
Figure 3 The downregulation of CD47 enhanced the colony formation and induced phagocytosis of melanoma cells by macrophages. (a) 
Cell proliferation of B16F10 cells transfected with anti-CD47 or control siRNA at different concentrations (n = 3). Neither the deficiency of CD47 
or the delivery vector caused any cytotoxicity to B16F10 cells. (b) Quantification of matrigel-based migration assay (n = 3). The loss of CD47 did 
not prohibit the migration of the B16F10 cells (Student’s t-test; n.s., not significant; P > 0.05). (c) Top: representative images of agarose gel colony 
formation assay. Bottom: quantification of colonies based on manual counting (n = 3) (Student’s t-test, *P < 0.05). The silencing of CD47 in B16F10 
cells led to an elevated level of anchorage-independent colony formation capacity. (d) Silencing of CD47 triggered phagocytosis of macrophages 
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Western-blot analysis (Figure 4d) and RT-PCR analysis (Figure 4e) 
of the tumor samples confirmed the efficient reduction of the CD47 
protein and mRNA levels in the tumors. In addition, liposomal clo-
dronate treatment did not impact on the CD47 expression in the 
tumor cells, which further supported that the tumor inhibition was 
CD47 and macrophage dependent. To assess the delivery specificity 
of the LPH-NPs, the infiltrated leukocytes in the solid tumors were 
isolated and stained with FITC-conjugated, anti-CD47 antibody 
for flowcytometry analysis (Supplementary Figure S3). Results 
indicated no significant difference regarding the CD47 expression 
level in leukocytes isolated from CD47 siRNA treated or untreated 
tumors, suggesting the high selectivity of the siRNA delivery medi-
ated by LPH-NPs and minimal impact on the immune system in 
the tumor microenvironment.
Systemic delivery of LPH-NPs containing anti-CD47 
siRNA to suppressed tumor metastasis
To evaluate if targeted delivery of anti-CD47 siRNA to cancer 
cells could be applied therapeutically against the homing of 
circulating cells in the lungs, we employed a well-established 
B16F10 metastasis model, which spontaneously developed 
lung metastasis after IV inoculation.21,26,27 LPH(CD47) were IV 
administered to the animals every 3 days beginning 3 days after 
inoculation (dose = 0.6 mg/kg) for a total of 5 injections. As 
shown in Figure 5a, there were fewer micrometastases in the 
lungs treated with LPH(CD47) than in the untreated control 
groups. Because the B16F10 melanomas were stably transfected 
with the firefly luciferase gene, the tumor metastasis could be 
quantified by measuring luciferase activity in the homogenates 
Figure 4 Intravenous administration of LPH(CD47) NP inhibited B16F10 solid tumor growth. (a) IV injection LPH(CD47) NP inhibited B16F10 
tumor growth. Tumor n = 5–7 per group, error bars show mean ± SEM (**P < 0.01, ***P < 0.0001 one-way analysis of variance). (b) Images of 
representative of tumors collected from the endpoint of the experiment. (c) Immunofluorescence staining of CD47 on tumor tissues collected. The 
nucleus was stained with DAPI and CD47 was stained with FITC-conjugated, anti-CD47 antibody. (d) Western-blot analysis of CD47 protein level in 
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of the lungs (Figure 5b). The results demonstrated decreased 
homing of melanoma cells, ~27% of that of the untreated con-
trol. The histological analysis of the lung tissues after treatment 
using hematoxylin and eosin stain showed fewer and smaller 
lung micrometastases observed in LPH(CD47)-treated ani-
mals (Figure 5c), as were indicated by melanin-containing cells 
in the lung. However, the tissues appeared dense and fibrotic 
which suggested that parenchyma of the lung tissues have been 
replaced or filled with stromal cells recruited by the tumor cells 
regardless of the treatments by the time the experiment was 
terminated. On the basis of these results, we conclude that the 
delivery of control siRNA did not elicit any therapeutic effects. 
To confirm the LPH(CD47) mediated therapeutic effect, we 
have performed a dose-dependence study with this lung metas-
tasis model by dosing the animals with various amounts of anti-
CD47 siRNA (0.2–0.6 mg/kg) encapsulated in the LPH-NPs, 
following the exactly same protocol. The results indicated a 
dose-responsive trend of the tumor growth inhibition by show-
ing a lower tumor loading with a higher drug dose, which sup-
ported the hypothesis that knockdown of CD47 in the tumor 
cells inhibited formation and proliferation of lung metastases 
(Supplementary Figure S4).
Systemic delivery of anti-CD47 siRNA in LPH-NPs 
caused no systemic organ damage or anemia
One of the over-arching goals of pharmaceutical sciences is to 
reduce undesired adverse effects through improvement of the 
pharmacokinetic profiles and biodistributions of therapeutic 
agents. To evaluate whether systemic administration of CD47 
siRNA caused any side effects to circulating hematopoietic cells, 
a hematology examination was performed on the blood samples 
collected from animals receiving injections of LPH(CD47) every 
48 hours (dose = 0.6 mg/kg) for a total of 6 injections. The cell 
counts of LPH(CD47) treated mice were not significantly different 
from the control groups (Figure 6a).
Mice repeatedly dosed with LPH(CD47) demonstrated that 
the administration of CD47 siRNA in an LPH formulation did 
not cause anemia. This might be expected because PEGylated NPs 
can inhibit uptake of particles by leukocytes.28 The major concern 
regarding the antibody therapy was resolved through the utili-
zation of the NP formulation, which altered the tropism of the 
therapeutics and avoided the side effects. Although there was an 
inevitable amount of accumulation of NPs in the liver and kidney, 
blood biochemistry tests showed that no detectable damage was 
caused; aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT) and blood urea nitrogen (BUN) analyses were all 
within normal range (Figure 6b). A western-blot analysis of all 
major organs showed that accumulation of LPH(CD47) NPs did 
not downregulate CD47 expression significantly compared to the 
untreated control (Supplementary Figure S5).
DISCUSSION
In this study, it was observed that the expression level of CD47 was 
elevated in clinical melanoma samples compared to that of mela-
nocytes, similar to levels measured in leukemic cells, lymphoma 
and other cancerous cells. Instead of antibody-based therapy, we 
used an alternative therapeutic approach, RNA interference. By 
systemically delivering anti-CD47 siRNA encapsulated in the 
LPH-NPs, we were able to block the inhibitory signal on the can-
cer cells that prevented them from being phagocytosed by mac-
rophages, resulting in a significant inhibition of melanoma solid 
tumor growth and dissemination of metastasis.
Figure 5 Intravenous administration of LPH(CD47) NP inhibited the growth of B16F10 lung metastasis. (a) Images of B16F10 metastasis bear-
ing lung harvested on day 18 after inoculation. (b) Quantitation of tumor load on the lung lobe determined by luciferase activity (n = 5) (Student’s 
t-test, *P < 0.05, ***P < 0.001). (c) Representative images of hematoxylin and eosin staining of the lung tissues harvested from treated animals. Arrows 
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High invasiveness and metastasis of melanoma requires the 
cells to be able to survive or evade the innate immune system 
once they are detached from the immunosuppressive primary 
microenvironment and until they establish a metastatic site. 
Therefore, the capacity to be immunologically tolerant is criti-
cal to the metastasis of the melanoma. CD47 is a receptor that is 
ubiquitously expressed on cell surfaces; it conveys a “self ” signal 
to the macrophages to limit clearance from the system. This trans-
membrane receptor has received much attention recently because 
malignant cells exhibit elevated expression of CD47 to counteract 
the pro-phagocytic stimulus of the abnormal expression profile 
of surface proteins recognized by macrophages.29 The analysis 
of CD47 levels in melanoma patients suggested a mechanism 
of immunologically sculpting tumor development, enabling the 
escape of the immune surveillance and providing a rational for 
therapies developed against this molecule. The finding led to the 
generation of the hypothesis with significant translation poten-
tial that silencing the CD47 receptor with siRNA as a therapeu-
tic approach could inhibit melanoma progression and metastasis. 
Although the interactions between SIRPα and CD47 have been 
demonstrated across species,15,19 the ligation should be classified 
as antagonistic to phagocytosis rather than “recognition” of the 
self-marker.30 Therefore we used the immune-tolerant B16F10 
murine melanoma cell line and the host strain C57BL/6 as an 
in vivo tumor model to validate the anti-cancer efficacy of RNAi 
therapy against CD47.
Apart from the anti-phagocytic activity, CD47 is also engaged 
in signal transductions that regulate cellular calcium concentra-
tion,31,32 apoptosis,33,34 proliferation,35,36 and even stress resis-
tance.37–39 Most of the physiological activities of CD47 were 
studied by using monoclonal antibodies or peptides, which 
could be either agonists or antagonists to the particular recep-
tor. Therefore, the reports outlining CD47’s roles in cell survival, 
proliferation, and migration that are seemingly paradoxical, can 
be attributed to the choices of agents in the studies. For example, 
some CD47 antibodies not only block the ligation between SIRPα 
and CD47, they also stimulate antibody-dependent, cell-mediated 
toxicity.40 In contrast, removal of CD47 with RNA interference 
provides an alternative approach to demonstrate the physiological 
functions of CD47.
The results of an MTS assay and a migration assay show that 
the deficiency of CD47 does not influence the cell viability or 
invasiveness in the short term (Figure 3a,b). However, an aga-
rose colony formation assay revealed an enhanced cell prolifera-
tion capacity, which was independent of external and internal 
stimuli (Figure 3c), a more reliable means to examine the extent 
of cell transformation. Interestingly, there were no reports on the 
characteristics on the CD47 deficient cancer cells, particularly 
Figure 6 Repeated administration of LPH(NP) NP caused minimal major organ toxicity or hematotoxicity. (a) Hematology test of whole blood 
collected from mice treated with multiple dose of LPH-NPs loaded with anti-CD47 siRNA (n = 5). (b) Blood biochemistry test of serum collected 
from mice treated with multiple doses of LPH-NPs. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; HCT, 
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those knocked down by RNAi. However, a series of experiments 
conducted on CD47 null mice have shown that the absence of 
CD47 could protect tissues from death caused by ionizing radia-
tion.38 The radio-resistance manifested by the primary cells 
cultured from the CD47 null mice showed that this effect is cell-
autonomous.41 Furthermore, a significant increase in the forma-
tion of autophagosomes has been observed in T cells lacking 
CD47 after irradiation, suggesting a mechanism for enhanced 
cell survival.42
The in vivo data was consistent with our colony formation 
data, which demonstrated an enhanced tumor growth induced 
by CD47 deficiency. This enhancement was observed in subcu-
taneous models (Figure 4a), when the tumor-associated macro-
phages were depleted by intraperitoneal injection of liposomal 
clodronate.25 In a syngeneic model of melanoma, however, the 
knockdown of CD47 in the presence of macrophages resulted 
in a significant inhibition of tumor growth (Figure 4a). The 
subcutaneous model data provided evidence to support that 
macrophage is the major player in the RNAi therapy targeting 
CD47. The same therapeutic effect was also demonstrated in 
a lung metastatic model, which supported the hypothesis that 
silencing of CD47 expression abolishes the anti-phagocytic sig-
nal of the cancer cells, disturbs the homeostasis between the 
pro- and anti-phagocytic surface markers and inhibits tumor 
growth and dissemination as a result of enhanced engulfment 
by macrophages.
siRNA-based therapeutics delivered by LPH-NPs signifi-
cantly extended the half-life, increased bioavailability22 and, most 
importantly, stringently controlled the tropism of therapeutics. 
The NPs accumulated in the proximity of the cancer cells due to 
the enhanced permeability and retention effects in the tumors 
with poorly arranged vasculature.43 The surface-functionalized, 
targeting ligands on the NPs then facilitate the receptor-mediated 
internalization and promote drug release. Therefore CD47 siRNA 
could be delivered in a targeted fashion through the exploitation 
of a ligand for a more unique and tumor-specific receptor than the 
ubiquitously expressed CD47.
Conversely, antibody-based therapeutics target and exert bio-
logical activities on the same molecules that are expressed in the 
cytoplasmic membrane, regardless of their cellular population. 
The limitation restricts the application of antibody-based ther-
apy because CD47 is ubiquitously expressed on all cell popula-
tions, particularly hematopoietic cells. As was observed, a single 
injection of mouse anti-CD47 antibody reduced the levels of red 
blood cells, hemoglobin, hematocrit and platelets to 60–80% of 
their original levels.19 These levels did not completely recover 
until 6 days after administration. In contrast, repeated injec-
tions of the LPH-NPs loaded with siRNA effectively inhibited 
tumor growth while maintaining blood parameters even after 6 
administrations(Figure 6a). Therefore, this method provides an 
efficacious and safer approach to target CD47 for cancer therapy.
Conclusion
Our study using melanoma as a model has conclusively demon-
strated that CD47 is an excellent target for RNAi-mediated cancer 
therapy. B16F10 is among the most aggressive murine tumors; 
it is fast growing and highly metastatic. A single therapeutic 
agent, i.e., siRNA, cannot control its growth in both solid tumor 
and metastasis. LPH formulation is a versatile platform that can 
codeliver siRNA, plasmid DNA and chemodrugs into individual 
cancer cells to exert synergistic anti-tumor effects.44 Complete 
eradication of the tumor could be possible if RNAi or gene/chemo 
therapies are codelivered to target multiple signaling pathways. 
Thus, LPH(CD47) may represent a starting point of treating very 
aggressive tumors, such as melanoma.
MATERIALS AND METHODS
Materials. 1,2-dioleoyl-3-trimethylammonium-propane chloride salt 
(DOTAP), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
(methoxy (polyethyleneglycol)-2000) ammonium salt (DSPE-PEG2000) 
were purchased from Avanti Polar Lipids (Alabaster, AL). Hyaluronic 
acid (HA), cholesterol (Chol), and protamine sulfate (fraction × from 
salmon) was purchased Sigma-Aldrich (St Louis, MO). All the other 
chemicals were purchased from Sigma-Aldrich unless otherwise 
mentioned. DSPE-PEG-AA was synthesized according to the previ-
ously established protocol.45 The mouse CD47 siRNA with sequence 
5′-GGAAUGACCUCUUUCACCA-3′ and the control siRNA with 
sequence 5′-AATTCTCCGAACGTGTCACGT-3′ were synthesized by 
Sigma-Aldrich.
Cell culture. Murine melanoma B1610 cells were used in this study. The 
cells were purchased from American Tissue Culture Collection. The cells 
were stably transduced with GL3 firefly luciferase gene with a retroviral 
vector by Pilar Blancafort’s laboratory at the University of North Carolina 
at Chapel Hill. Cells were maintained in DMEM (Life Technologies, 
Carlsbad, CA) with 10% fetal bovine serum (Life Technologies).
Experimental animals. Female C57BL/6 mice of 6–8 weeks old were 
purchased from the National Cancer Institute (Frederick, MD). Female 
C57BL/6-Tg(UBC-GFP)30Scha/J mice of 6–8 weeks old were purchased 
from the Jackson laboratory (Bar Harbor, Maine). All animal proto-
cols were approved by the University of North Carolina at Chapel Hill’s 
Institutional Animal Care and Use Committee.
Processing human melanoma samples. Experiments involved 
human materials were conducted in Gavin P Robertson’s laboratory at 
Pennsylvania State University according to the protocol approved by the 
institutional Review Board Committee. Samples preparation for western 
blot was performed according to previously published protocol.46 Briefly, 
sixteen tissues samples were acquired at surgery, snap frozen in liquid 
nitrogen and pulverized using a mortar and pestle. Cell debris were pel-
leted by centrifugation (≥10,000g) and the protein concentrations of the 
supernatant were quantified. A western-blot analysis was then performed 
using these samples to assess the CD47 protein level.
Preparation of liposome and LPH. LPH-NPs were formulated through 
a stepwise self-assembly process based on a well-established protocol.20 
DOTAP and Chol (1:1, mol/mol) were dissolved in chloroform and sol-
vent was removed under reduced pressure. The lipid film is hydrated 
overnight with distilled water to make the final concentration 10 mmol/l 
DOTAP and cholesterol. The liposome was sequentially extruded through 
400 nm, 200 nm, 100 nm, and 50 nm polycarbonate membranes (Millipore, 
Billerica, MA) to form 80–100 nm unilamellar liposomes. The LPH core 
was formed by mixing 140 μl of solution A (24 μg siRNA and 24 μg HA in 
5% glucose) and 140 µl of solution B (36 μg protamine in 5% glucose). The 
mixed solution was incubated at room temperature for 10 minutes before 
60 μl DOTAP/Chol liposome (10 mmol/l each) was added. PEGylation 
was performed by adding 30 μl DSPE-PEG (10 mg/ml) and 30 μl DSPE-
PEG-AA (10 mg/ml) to the LPR and incubating the mix at 50 °C for 
15 minutes. The size and surface charge of the NPs were determined by 
using a Malvern ZS90 Zetasizer (Worcestershire, UK).
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Liposomal clodronate was prepared according a well-
established protocol,25 implementing only minor modifications. Soy 
phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) (0.4 g) and 
0.06 g of cholesterol was dissolved in chloroform and solvent was removed 
under reduced pressure. The lipid membrane was then rehydrated 
overnight with phosphate buffer (20 mmol/l, pH 7.4) containing 0.211 g 
clodronate (Sigma-Aldrich). The liposome was sequentially extruded 
through 400 nm, 200 nm, 100 nm, and 50 nm polycarbonate membranes 
(Millipore) to form 80–100 nm unilamellar liposomes. The prepared 
liposomes contained ~20 mg/ml clodronate.
Western-blot analysis. Clinical samples and melanocyte were lysed with a 
radioimmunoprecipitation assay buffer. Protein concentration was deter-
mined using the Bradford protein assay reagents according to the manu-
facturer’s protocols. Protein samples for western blotting were diluted in 
4× sample buffer containing reducing reagent and heated at 95 °C for 5 
minutes. Proteins were resolved by electrophoresis on NuPAGE 4–12% 
Bis-Tris Gels (Life Technologies), transferred to Immobilon-P transfer 
membrane (Millipore) and probed with anti-CD47 mAb (Santa Cruz, 
Santa Cruz, CA) or anti-GAPDH mAb (Cell Signaling, Danvers, MA) fol-
lowed by the horseradish peroxidase-conjugated secondary antibodies, 
respectively, and detected using the Pierce ECL Western Blotting Substrate 
(Thermo Fisher Scientific, Rockford, IL). The relative CD47 expression 
level was determined with ImageJ software (National Institutes of Health, 
Bethesda, MD) using GAPDH as a loading control.
In vitro transfection. Six-well plates were seeded with 1 × 105 cells per well. 
LPH loaded with CD47 or control siRNA was added to each well in the 
presence of OptiMEM medium with final concentration of 250 nmol/l. 
The medium was replaced with full medium 4 hours after transfection and 
the cells were incubated overnight. The CD47 protein levels of samples 
after transfection were determined by western-blot analysis with GAPDH 
as loading control.
MTS cell proliferation assay. For short-term proliferation assay, 96-well 
plates were seeded with 5 × 103 cells per well and transfected with 
LPH(CD47) or LPH(Con) NPs equivalent to 250 nmol/l anti-CD47 siRNA. 
Twenty-four after transfection, cells were subject to MTS assay (Promega, 
Madison, MI) according to the manufacture’s instruction. For long-term 
proliferation assay, six-well plates were seeded with 1 × 105 cells per well. 
Cells were transfected with NPs equivalent to 0–250 nmol/l siRNA and 
seeded into 96-well plate with a seeding density of 100 cells per well. Cells 
were then subjective to MTS assay 7 days after transfection.
Colony formation analysis in soft agar. Anchorage-independent cell 
growth was analyzed by plating 0.35% top agarose containing 1 × 105 
LPH-NPs transfected cells mixed with complete medium on a surface of 
0.5% bottom agarose mixed with complete medium. Cells were fed twice 
weekly by adding fresh medium. After 2 weeks of incubation, colonies 
were stained with crystal violet solution, photographed and counted with 
Gel Doc Imaging system (Bio-Rad, Hercules, CA). Each experiment was 
performed in triplicate and repeated three times.
Invasion assay. Six-well BD BioCoat Matrigel Invasion chamber (Becton 
Dickinson, Franklin Lakes, NJ) were rehydrated for 2 hours in 37 °C with 
complete medium containing 10% FBS and 1% PS. LPH-NPs transfected 
cells were suspended with basal medium containing 5 × 104 cells and 
added to each insert Complete medium was added to the well as a chemo-
attractant. After incubation for 24 hours, non-invading cells were removed 
from the upper side of the membrane by scrubbing. Invasion of cells was 
detected by staining the cells with crystal violet solution and visualizing 
the cells under a microscope. Cells were counted under an inverted micro-
scope in four randomly selected fields (magnification ×100), and results 
were expressed in the form of a bar graph. Assays were performed three 
times for each treatment.
In vitro phagocytosis assay. The in vitro phagocytosis was determined 
according to the published protocol with modification.19 Briefly, C57BL/6 
were transfected with plasmid DNA encoding Tdtomato RFP (Clontech 
Laboratories, Mountain View, CA) with Lipofectamine 2000 (Life 
Technologies) for 2 consecutive days to ensure over 90% transfection 
activity. The macrophages were collected from GFP-expressing C57BL/6 
transgenic mice (the Jackson Laboratory) to ensure CD47-SIPRα compat-
ibility. The inflammatory response of transgenic mice was stimulated by 
intraperitoneal injection of 3% proteose peptone (Sigma-Aldrich) in 1 ml 
of Dulbecco’s phosphate-buffered saline (DPBS). Three days after stimu-
lation, mice were euthanized and macrophages were harvested from the 
peritoneal cavity. The RFP-expressing B16F10 cells were transfected with 
LPH(CD47) or LPH(con). One day after transfection, the primary murine 
macrophages were incubated with transfected B16F10 cells in the serum 
free media and observed under the Olympus FV1000 MPE SIM Laser 
Scanning Confocal Microscope (Olympus, Center Valley, PA). The images 
with dual channel were acquired every 2 minutes. The phagocytic index 
was determined as the number of phagocytosed RFP-expressing cells per 
100 macrophages (GFP-expressing).
In vivo transfection study. LPH-NPs equivalent to 12 μg of CD47 siRNA 
or control siRNA prepared as aforementioned were IV injected into the 
subcutaneous-tumor–bearing, nude mice. Mice were killed 24 hours after 
injection. Organs and tumor tissues were homogenized and the tissue 
lysates were subject to luciferase assay (Promega, Madison, MI) according 
to manufacture’s instructions.
Tumor growth inhibition/metastasis inhibition assay. B16F10 cells 
were harvested and suspended in DPBS with concentration 2 × 105 
cells/50 μl. C57BL/6 mice of 6–8 weeks old were inoculated with B16F10 
cells by subcutaneously injecting 2 × 105 B16F10 cells in 50 μl DPBS on 
the hind legs. Tumor bearing animals received LPH-NPs treatment 
started from 8th day after inoculation when the tumor volumes reached 
50 mm3. LPH-NPs equivalent to 12 μg of CD47 or control siRNA 
(0.6 mg/kg), prepared as described above, were IV injected every other 
day for a totally of 6 treatments. Tumor size was measured with a digital 
caliper (Thermo Fisher Scientific, Pittsburg, PA) and animal weight was 
monitored every 3 days. Tumor volume was calculated as (1/2 × length 
× width × height).
To deplete the tumor-associated macrophages, animals were subject 
to three intraperitoneal injections of liposomal clodronate with 100 mg/kg 
for the first dose and 50 mg/kg for the following two doses. The liposomal 
clodronate treatment started from day 3 after inoculation and lasted 
3 consecutive days.
The metastasis model was created by IV injecting 2 × 105 B16F10 cells 
in 100 μl DPBS into 6–8 week old C57BL/6 mice. LPH-NPs equivalent to 
12 µg siRNA (0.6 mg/kg) were IV administered to the mice every 3 days 
for a total of 5 treatments starting from 3 days after inoculation. Mice 
were killed and lungs were harvested on day 18 after inoculation. For the 
dose-dependence assay, animals were treated with LPH-NPs equivalent to 
0.2–0.6 mg/kg siRNA following the same treatment regime.
Flow cytometry. B16F10/Luc cells were seeded at 1 × 105 cells/well in six-
well plate 24 hours before the transfection. 24 hours after transfection, 
the cells were washed with PBS and collected by centrifugation. Cell sus-
pensions were stained with FITC-conjugated, anti-CD47 (Santa Cruz) or 
isotype control antibodies (Becton Dickinson, Franklin Lakes, NJ). CD47 
expression was analyzed by flow cytometry on a BD FACSAria instrument 
(Becton Dickinson). To stain tumor-infiltrating leukocytes, cells were iso-
lated from solid tumors after LPH-NPs treatment.
Quantitative RT-PCR. Quantitative RT-PCR analysis was performed with 
the SYBR Green kit (Life Technologies) and ABI prism 7500 Sequence 
Detector (Applied Biosystems, Foster City, CA). Total RNA from tumor 
tissues were extracted using an RNeasy kit (Qiagen,  Valencia,  CA). 
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cDNAs were synthesized with a SuperScript II reverse transcriptase 
kit (Life Technologies). Reactions were run using a standard cycling 
program; 50 °C for 2 minutes, 95 °C for 10 minutes, 40 cycles of 95 
°C for 15 seconds, and 60 °C for 1 minute. The PCR primers to detect 
mouse CD47 (forward; 5′- GTTCAGCTCAACTACTGT-3′, reverse; 
5′-CTCTTATTCGTATGGCTG-3′) and mouse actin (forward; 
5′- ATATCGCTGCGCTGGTCGTC-3′, reverse; 5′- AGGATGGCGTGA 
GGGAGAGC-3′) were synthesized and purified by IDT (Coralville, IA).
Immunofluorescence. Immunofluorescence detection of CD47 on tumor 
tissues was prepared using paraffin sections (obtained from the UNC 
Tissue Procurement Core) that were deparaffinized, antigen recovered and 
blocked at room temperature with 5% BSA/PBS for 1 hour, and incubated 
with FITC-conjugated, anti-CD47 antibodies (Santa Cruz) overnight 
at 4 °C. The slides were then washed with PBS and counter-stained with 
VECTORSHIELD mounting media with DAPI (VECTOR Laboratories, 
Burlingame, CA).
AST, ALT, BUN assay and hematology assay. Mice that were IV injected 
with LPH (equivalent to 24 μg CD47 siRNA or control siRNA) every other 
day for a total of 5 treatments were subjected to a toxicity assay. Sera and 
whole blood collected from the mice were assayed for AST, ALT, BUN, 
and hematological parameters performed by UNC facility. Organs were 
collected and fixed with 4% paraformaldehyde in PBS overnight before 
stained with hematoxylin and eosin by UNC histology facility.
Statistical analysis. Percentages of GFP-positive cells and MFIs were cal-
culated by BD CellQuest (BD Biosciences) software. Statistical analysis was 
undertaken using Prism 5.0c Software. A two-tailed t-test or a one-way 
analysis of variance was performed when comparing two groups or more 
than two groups, respectively. Statistical significance was defined by a value 
of P < 0.05.
SUPPLEMENTARY MATERIAL
Figure S1. Size and zeta potential characterization of core, mem-
brane-coated NP and pegylated LPH-NP.
Figure S2. Dose-dependence cell proliferation assay of B16F10 cells 
treated with various doses of LPH(CD47) NP.
Figure S3. Flowcytometry analysis of tumor-infiltrating leukocytes 
collected from the tumors tissues of the tumor-bearing mice treated 
with the LPH-NPs.
Figure S4. Quantitation of B16F10 tumor load on the lung deter-
mined by luciferase activity after treatment of LPH(CD47) NP with vari-
ous doses (n = 3).
Figure S5. Western-blot analysis of CD47 expression levels in the 
major organs collected from the untreated animals and the animals 
that received multiple treatments of LPH(CD47) NP.
ACKNOWLEDGMENTS
This work was supported by NIH grants CA129835, CA129421, 
CA151652, CA151455, and CA149363. We thank Kelly Ann Racette 
for manuscript editing. The authors declared no conflict of interest.
REFERENCES
1. Liang, S, Sharma, A, Peng, HH, Robertson, G and Dong, C (2007). Targeting mutant 
(V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and 
melanoma extravasation. Cancer Res 67: 5814–5820.
2. Cipponi, A, Wieers, G, van Baren, N and Coulie, PG (2011). Tumor-infiltrating 
lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol 
Immunother 60: 1153–1160.
3. Parmiani, G, Castelli, C, Santinami, M and Rivoltini, L (2007). Melanoma immunology: 
past, present and future. Curr Opin Oncol 19: 121–127.
4. Umansky, V and Sevko, A (2012). Melanoma-induced immunosuppression and its 
neutralization. Semin Cancer Biol 22: 319–326.
5. Ostrand-Rosenberg, S (2008). Immune surveillance: a balance between protumor and 
antitumor immunity. Curr Opin Genet Dev 18: 11–18.
6. Kusmartsev, S and Gabrilovich, DI (2006). Effect of tumor-derived cytokines and 
growth factors on differentiation and immune suppressive features of myeloid cells in 
cancer. Cancer Metastasis Rev 25: 323–331.
7. Rivoltini, L, Canese, P, Huber, V, Iero, M, Pilla, L, Valenti, R et al. (2005). Escape 
strategies and reasons for failure in the interaction between tumour cells and the 
immune system: how can we tilt the balance towards immune-mediated cancer 
control? Expert Opin Biol Ther 5: 463–476.
8. Frazier, WA, Gao, AG, Dimitry, J, Chung, J, Brown, EJ, Lindberg, FP et al. (1999). The 
thrombospondin receptor integrin-associated protein (CD47) functionally couples to 
heterotrimeric Gi. J Biol Chem 274: 8554–8560.
9. Oldenborg, PA, Zheleznyak, A, Fang, YF, Lagenaur, CF, Gresham, HD and Lindberg, 
FP (2000). Role of CD47 as a marker of self on red blood cells. Science 288: 
2051–2054.
10. Jaiswal, S, Jamieson, CH, Pang, WW, Park, CY, Chao, MP, Majeti, R et al. (2009). CD47 
is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid 
phagocytosis. Cell 138: 271–285.
11. Majeti, R, Chao, MP, Alizadeh, AA, Pang, WW, Jaiswal, S, Gibbs, KD Jr et al. (2009). 
CD47 is an adverse prognostic factor and therapeutic antibody target on human 
acute myeloid leukemia stem cells. Cell 138: 286–299.
12. Chan, KS, Espinosa, I, Chao, M, Wong, D, Ailles, L, Diehn, M et al. (2009). 
Identification, molecular characterization, clinical prognosis, and therapeutic targeting 
of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106: 14016–14021.
13. Chao, MP, Alizadeh, AA, Tang, C, Myklebust, JH, Varghese, B, Gill, S et al. (2010). 
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate 
non-Hodgkin lymphoma. Cell 142: 699–713.
14. Dunn, GP, Old, LJ and Schreiber, RD (2004). The three Es of cancer immunoediting. 
Annu Rev Immunol 22: 329–360.
15. Kim, D, Wang, J, Willingham, SB, Martin, R, Wernig, G and Weissman, IL (2012). Anti-
CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma 
cells. Leukemia 26: 2538–2545.
16. Edris, B, Weiskopf, K, Volkmer, AK, Volkmer, JP, Willingham, SB, Contreras-Trujillo, 
H et al. (2012). Antibody therapy targeting the CD47 protein is effective in a 
model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109: 
6656–6661.
17. Chao, MP, Tang, C, Pachynski, RK, Chin, R, Majeti, R and Weissman, IL (2011). 
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited 
by anti-CD47 antibody therapy. Blood 118: 4890–4901.
18. Chao, MP, Alizadeh, AA, Tang, C, Jan, M, Weissman-Tsukamoto, R, Zhao, F et 
al. (2011). Therapeutic antibody targeting of CD47 eliminates human acute 
lymphoblastic leukemia. Cancer Res 71: 1374–1384.
19. Willingham, SB, Volkmer, JP, Gentles, AJ, Sahoo, D, Dalerba, P, Mitra, SS et al. (2012). 
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target 
for human solid tumors. Proc Natl Acad Sci USA 109: 6662–6667.
20. Chono, S, Li, SD, Conwell, CC and Huang, L (2008). An efficient and low 
immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. 
J Control Release 131: 64–69.
21. Chen, Y, Zhu, X, Zhang, X, Liu, B and Huang, L (2010). Nanoparticles modified with 
tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18: 
1650–1656.
22. Li, SD and Huang, L (2010). Stealth nanoparticles: high density but sheddable PEG is 
a key for tumor targeting. J Control Release 145: 178–181.
23. Tyner, JW, Uchida, O, Kajiwara, N, Kim, EY, Patel, AC, O’Sullivan, MP et al. (2005). 
CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during 
viral infection. Nat Med 11: 1180–1187.
24. Seiler, P, Aichele, P, Odermatt, B, Hengartner, H, Zinkernagel, RM and Schwendener, 
RA (1997). Crucial role of marginal zone macrophages and marginal zone metallophils 
in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol 27: 
2626–2633.
25. Zeisberger, SM, Odermatt, B, Marty, C, Zehnder-Fjällman, AH, Ballmer-Hofer, K and 
Schwendener, RA (2006). Clodronate-liposome-mediated depletion of tumour-
associated macrophages: a new and highly effective antiangiogenic therapy approach. 
Br J Cancer 95: 272–281.
26. Yang, Y, Li, J, Liu, F and Huang, L (2012). Systemic delivery of siRNA via LCP 
nanoparticle efficiently inhibits lung metastasis. Mol Ther 20: 609–615.
27. Li, SD, Chono, S and Huang, L (2008). Efficient oncogene silencing and metastasis 
inhibition via systemic delivery of siRNA. Mol Ther 16: 942–946.
28. Gref, R, Minamitake, Y, Peracchia, MT, Trubetskoy, V, Torchilin, V and Langer, 
R (1994). Biodegradable long-circulating polymeric nanospheres. Science 263: 
1600–1603.
29. Chao, MP, Jaiswal, S, Weissman-Tsukamoto, R, Alizadeh, AA, Gentles, AJ, Volkmer, J 
et al. (2010). Calreticulin is the dominant pro-phagocytic signal on multiple human 
cancers and is counterbalanced by CD47. Sci Transl Med 2: 63ra94.
30. Subramanian, S, Parthasarathy, R, Sen, S, Boder, ET and Discher, DE (2006). Species- 
and cell type-specific interactions between CD47 and human SIRPalpha. Blood 107: 
2548–2556.
31. Schwartz, MA, Brown, EJ and Fazeli, B (1993). A 50-kDa integrin-associated protein 
is required for integrin-regulated calcium entry in endothelial cells. J Biol Chem 268: 
19931–19934.
32. Sick, E, Niederhoffer, N, Takeda, K, Landry, Y and Gies, JP (2009). Activation of 
CD47 receptors causes histamine secretion from mast cells. Cell Mol Life Sci 66: 
1271–1282.
33. Pettersen, RD, Hestdal, K, Olafsen, MK, Lie, SO and Lindberg, FP (1999). CD47 signals 
T cell death. J Immunol 162: 7031–7040.
34. Manna, PP and Frazier, WA (2004). CD47 mediates killing of breast tumor cells via 
Gi-dependent inhibition of protein kinase A. Cancer Res 64: 1026–1036.
35. Sick, E, Boukhari, A, Deramaudt, T, Rondé, P, Bucher, B, André, P et al. (2011). 
Activation of CD47 receptors causes proliferation of human astrocytoma but not 
normal astrocytes via an Akt-dependent pathway. Glia 59: 308–319.
36. Congote, LF and Temmel, N (2004). The C-terminal 26-residue peptide of serpin A1 
stimulates proliferation of breast and liver cancer cells: role of protein kinase C and 
CD47. FEBS Lett 576: 343–347.
1928 www.moleculartherapy.org vol. 21 no. 10 oct. 2013
© The American Society of Gene & Cell Therapy
Targeted LPH Delivery Inhibits Tumor Growth by Silencing CD47
37. Lih, CJ, Wei, W and Cohen, SN (2006). Txr1: a transcriptional regulator of 
thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 20: 
2082–2095.
38. Maxhimer, JB, Soto-Pantoja, DR, Ridnour, LA, Shih, HB, Degraff, WG, Tsokos, M et al. 
(2009). Radioprotection in normal tissue and delayed tumor growth by blockade of 
CD47 signaling. Sci Transl Med 1: 3ra7.
39. Maxhimer, JB, Shih, HB, Isenberg, JS, Miller, TW and Roberts, DD (2009). 
Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue 
protective. Plast Reconstr Surg 124: 1880–1889.
40. Sick, E, Jeanne, A, Schneider, C, Dedieu, S, Takeda, K and Martiny, L (2012). CD47 
update: a multifaceted actor in the tumour microenvironment of potential therapeutic 
interest. Br J Pharmacol 167: 1415–1430.
41. Isenberg, JS, Maxhimer, JB, Hyodo, F, Pendrak, ML, Ridnour, LA, DeGraff, WG et al. 
(2008). Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. 
Am J Pathol 173: 1100–1112.
42. Soto-Pantoja, DR, Miller, TW, Pendrak, ML, DeGraff, WG, Sullivan, C, Ridnour, LA et 
al. (2012). CD47 deficiency confers cell and tissue radioprotection by activation of 
autophagy. Autophagy 8: 1628–1642.
43. Matsumura, Y and Maeda, H (1986). A new concept for macromolecular therapeutics 
in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and 
the antitumor agent smancs. Cancer Res 46(12 Pt 1): 6387–6392.
44. Chen, Y, Bathula, SR, Li, J and Huang, L (2010). Multifunctional nanoparticles 
delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. 
J Biol Chem 285: 22639–22650.
45. Banerjee, R, Tyagi, P, Li, S and Huang, L (2004). Anisamide-targeted stealth liposomes: 
a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 
112: 693–700.
46. Huh, SJ, Chung, CY, Sharma, A and Robertson, GP (2010). Macrophage inhibitory 
cytokine-1 regulates melanoma vascular development. Am J Pathol 176:  
2948–2957.
Molecular Therapy vol. 21 no. 10 oct. 2013 1929
